[
    [
        {
            "time": "",
            "original_text": "分红转增比例与业绩增幅相配？健帆生物遭监管 其他违规处罚",
            "features": {
                "keywords": [
                    "分红",
                    "转增",
                    "业绩",
                    "健帆生物",
                    "监管",
                    "违规处罚"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "分红转增比例与业绩增幅相配？健帆生物遭监管 其他违规处罚",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "鹰眼预警:健帆生物产品结构较单一 存货周转能力下滑 经营问题",
            "features": {
                "keywords": [
                    "健帆生物",
                    "产品结构",
                    "单一",
                    "存货周转",
                    "经营问题"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "鹰眼预警:健帆生物产品结构较单一 存货周转能力下滑 经营问题",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【面包财经】健帆生物：2019年归母净利润5.71亿元，同比增长42%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2019年",
                    "归母净利润",
                    "同比增长",
                    "42%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【面包财经】健帆生物：2019年归母净利润5.71亿元，同比增长42%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物因拟转增扩张股本收深交所关注函 关注函",
            "features": {
                "keywords": [
                    "健帆生物",
                    "转增",
                    "扩张股本",
                    "深交所",
                    "关注函"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物因拟转增扩张股本收深交所关注函 关注函",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物收关注函：说明通过本次转增扩张股本的主要考虑及其合理性、必要性 关注函",
            "features": {
                "keywords": [
                    "健帆生物",
                    "转增",
                    "扩张股本",
                    "合理性",
                    "必要性",
                    "关注函"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物收关注函：说明通过本次转增扩张股本的主要考虑及其合理性、必要性 关注函",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物收关注函，说明本次分红预案是否与公司业绩增长幅度相匹配 关注函",
            "features": {
                "keywords": [
                    "健帆生物",
                    "分红预案",
                    "业绩增长",
                    "匹配",
                    "关注函"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物收关注函，说明本次分红预案是否与公司业绩增长幅度相匹配 关注函",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物（300529）：业绩符合预期，肾病领域空间广阔【2019年报点评|西南医药朱国广/杜向阳团队】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "业绩",
                    "预期",
                    "肾病领域",
                    "空间广阔",
                    "2019年报"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物（300529）：业绩符合预期，肾病领域空间广阔【2019年报点评|西南医药朱国广/杜向阳团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "健帆生物2019营收增长40.86% 拟分红3.76亿元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2019",
                    "营收增长",
                    "40.86%",
                    "分红",
                    "3.76亿元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物2019营收增长40.86% 拟分红3.76亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物(300529): 年报业绩维持高增长，看好20年增长潜力",
            "features": {
                "keywords": [
                    "健帆生物",
                    "年报",
                    "高增长",
                    "20年",
                    "增长潜力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529): 年报业绩维持高增长，看好20年增长潜力",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]